239 results about "Pain sensations" patented technology

Devices, systems and methods are provided for treating pain while minimizing or eliminating possible complications and undesired side effects, particularly the sensation of paresthesia. This is achieved by stimulating in proximity to a dorsal root ganglion with stimulation energy in a manner that will affect pain sensations without generating substantial sensations of paresthesia. In some embodiments, such neurostimulation takes advantage of anatomical features and functions particular to the dorsal root ganglion.

The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic alpha-adrenergic receptor in the absence of alpha-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic alpha-adrenergic receptor can be, for example, the alpha-2B receptor.

A method of detecting pain in a subject, comprises the steps of generating brain wave data based on brain wave activity of the subject and comparing the brain wave data to reference data to generate result data, the reference data corresponding to at least one of (i) population normative data indicative of brain wave activity of a first plurality of individuals in an absence of pain, (ii) population reference data indicative of brain wave activity of a second plurality of individuals generated in response to pain events inflicted on the second plurality of individuals, (iii) subjective population reference data indicative of brain wave activity of a third plurality of individuals reporting a sensation of pain, and (iv) population of reference data indicative of brain wave activity of a fourth population of individuals following an intervention which has changed a subjective report of pain in combination with determining a presence of pain experienced by the subject as a function of the result data.

Described herein is a novel fMRI-based neurologic signature that predicts pain. Further described are methods for detecting pain, for diagnosing pain-related neuropathic conditions and for predicting or evaluating efficacy of an analgesic based on the neurologic signature.

Neuromodulation devices and methods of their use are described in which a therapeutic device is configured to generate a treatment for treating pain such as the reduction of the symptoms of chronic and acute pain as well as for treating other conditions. The neuromodulation device generates an output electrical signal in the form of pulses with a fast rise-time spike waveform followed by a longer-duration, lower amplitude primary phase waveform. The output signal includes a broad range of frequency components, with time constants tuned so as to interact with specific cell membrane or cellular components. The output signal may be conducted to the patient via electrodes. The pulses are triggered at variable intervals which prevent habituation.

Neuromodulation devices and methods of their use are described in which a therapeutic device is configured to generate a treatment for treating pain such as the reduction of the symptoms of chronic and acute pain as well as for treating other conditions. The neuromodulation device generates an output electrical signal in the form of pulses with a fast rise-time spike waveform followed by a longer-duration, lower amplitude primary phase waveform. The output signal includes a broad range of frequency components, with time constants tuned so as to interact with specific cell membrane or cellular components. The output signal may be conducted to the patient via electrodes. The pulses are triggered at variable intervals which prevent habituation.

A method of detecting pain in a subject, comprises the steps of generating brain wave data based on brain wave activity of the subject and comparing the brain wave data to reference data to generate result data, the reference data corresponding to at least one of (i) population normative data indicative of brain wave activity of a first plurality of individuals in an absence of pain, (ii) population reference data indicative of brain wave activity of a second plurality of individuals generated in response to pain events inflicted on the second plurality of individuals, (iii) subjective population reference data indicative of brain wave activity of a third plurality of individuals reporting a sensation of pain, and (iv) population of reference data indicative of brain wave activity of a fourth population of individuals following an intervention which has changed a subjective report of pain in combination with determining a presence of pain experienced by the subject as a function of the result data.

The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.

Pharmaceutical compositions for the treatment of acute pain via sublingual administration are disclosed. The composition contains an ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of substantially anhydrous, microparticles adhered to substantially water-soluble particles that are much larger than the fentanyl particles. The surface of the carrier particles. In a preferred embodiment, the composition also contains a bioadhesion and / or mucoadhesion promoter. The invention also relates to a method for the preparation of the composition and the use of the composition for the treatment of acute pain.

The invention discloses a cold / hot pain stimulation system, which mainly solves the problem that the laser stimulation equipment in the prior art cannot refrigerate and is complex in operation and high in cost in a nuclear magnetic environment. The cold / hot pain stimulation system comprises a cold / hot stimulation head (1), a protective net (2), a heat radiation water tank (3), a water pump (4), a water storage tank (5), an embedded type control module (6) and an upper computer, wherein the cold / hot stimulation head (1), the heat radiation water tank (3), the water pump (4) and the water storage tank (5) are connected with each other in sequence to form a water circulation system through water pipes; the cold / hot stimulation head (1) is connected with the upper computer (7) through the embedded type control module (6); the embedded type control module (6) controls the cold / hot stimulation head (1) to stimulate human skin according to the stimulation temperature set by the upper computer; and the actual stimulation temperature and pain sensation scores are transmitted to the upper computer (7) for storage and display through the embedded type control module (6). The cold / hot pain stimulation system disclosed by the invention is easy in operation and safe in use, and can be used for studying the pain sensation and evaluating pain relieving effect in a nuclear magnetic environment.

A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

It has been discovered that pain felt in a given region of the body can be treated, not by motor point stimulation of muscle in the local region where pain is felt, but by stimulating muscle spaced from a “nerve of passage” in a region that is superior (i.e., cranial or upstream toward the spinal column) to the region where pain is felt. Spinal nerves such as the intercostal nerves or nerves passing through a nerve plexus, which comprise trunks that divide by divisions and / or cords into branches, comprise “nerves of passage.”

The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided.

The present disclosure is directed to a system and method for selectively and reversibly modulating targeted neural and non-neural tissue of a nervous system for the treatment of pain. An electrical stimulation is delivered to the treatment site that selectively and reversibly modulates the targeted neural- and non-neural tissue of the nervous structure, inhibiting pain while preserving other sensory and motor function, and proprioception.

The inventive method for processing an RR series comprises a plurality of (RR) samples representing time intervals (dti) between two successive heart beats or the inverse (1 / dti) of said time intervals consists in selecting (N) (RRi) samples in a main time window having a predetermined length (n), in cutting said main window into (m) subwindows (Fj), in calculating an intermediate parameter (A1) for each subwindow (Fj) on the basis of the (RRi) samples contained in the subwindow (Fj) and in calculating a final parameter as a function of the intermediate parameters (Aj).The invention is used for analysing a cardiac rhythm variability, in particular for assessing a patient's pain or stress.

The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.

The present disclosure is directed to a system and method modulating targeted neural and non-neural tissue of a nervous system for the treatment of head-and-face pain. Electrical stimulation is delivered transcutaneously to the treatment site that modulates the targeted neural- and non-neural tissue of the nervous structure, inhibiting nervous signaling and the perception of pain.

Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. In embodiments, the present disclosure provides a method for alleviating pain in a subject in need of treatment, the method comprising administering to the subject an effective amount of a saxitoxin analogue compound, or a pharmaceutically acceptable salt, isomer, tautomer or prodrug thereof, whereby pain in said subject is alleviated.